3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
3
Gynecologic
1
Conditions
Ovarian Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Peritoneal Neoplasms
1
Head and Neck Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Bile Duct Neoplasms
1
Appendiceal Neoplasms
1
Interventions
pembrolizumab
13
Nivolumab
6
Gemcitabine
5
Paclitaxel
4
Cisplatin
4
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Fluorouracil
3
Fluorodeoxyglucose F18
3
Carboplatin
3
spartalizumab
2
fludarabine
2
budigalimab
2
Oxaliplatin
2
Leucovorin
2
Irinotecan
2
FAPI-46
2
Drug Therapy
2
Docetaxel
2
Cyclophosphamide
2
Bevacizumab
2
venetoclax
1
ulixertinib
1
tislelizumab
1
seribantumab
1
saracatinib
1
rovalpituzumab tesirine
1
pertuzumab
1
pemigatinib
1
nilotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
irinotecan sucrosofate
×
Gynecologic
×
Clear all
NCT05277766
2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1
Recruiting
45 enrolled